Immatics (IMTX) Net Income towards Common Stockholders (2019 - 2025)

Immatics (IMTX) reported Net Income towards Common Stockholders of -$41.2 million for Q4 2025, down 186.03% on a YoY basis from $47.9 million in Q4 2024, and up 30.55% sequentially from -$59.4 million in Q3 2025.

Immatics (IMTX) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends

Immatics (IMTX) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$41.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 186.03% year-over-year to -$41.2 million; the trailing twelve-month figure through Dec 2025 stood at -$226.5 million (down 1615.95% YoY), and the FY2025 full-year result was -$221.9 million, down 1447.51% from the prior year.
  • Net Income towards Common Stockholders improved to -$41.2 million in Q4 2025, from -$59.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $96.1 million in Q1 2022 to a low of -$81.9 million in Q2 2025.
  • A 5-year average of -$17.0 million and a median of -$23.4 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders jumped 449.38% in 2022 and sank 135050064.49% in 2025, its largest moves.
  • Tracing IMTX's Net Income towards Common Stockholders over 5 years: stood at -$19.2 million in 2021, then surged by 111.78% to $2.3 million in 2022, then plunged by 1343.81% to -$28.1 million in 2023, then soared by 270.4% to $47.9 million in 2024, then slumped by 186.03% to -$41.2 million in 2025.
  • Business Quant data shows IMTX's Net Income towards Common Stockholders at -$41.2 million in Q4 2025, -$59.4 million in Q3 2025, and -$81.9 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -625.73
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -0.68
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 366.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Immatics 1.11 Bn 1.11 Bn - -41.24 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -41.24 Mn
Sep 30, 2025 -59.39 Mn
Jun 30, 2025 -81.90 Mn
Mar 31, 2025 -44.01 Mn
Dec 31, 2024 47.94 Mn
Sep 30, 2024 -13.62 Mn
Jun 30, 2024 -19.38 Mn
Mar 31, 2024 -32.59
Dec 31, 2023 -28.13 Mn
Sep 30, 2023 -28.84 Mn
Jun 30, 2023 -26.80 Mn
Mar 31, 2023 -279.07
Dec 31, 2022 2.26 Mn
Sep 30, 2022 -19.98 Mn
Jun 30, 2022 -12.47 Mn
Mar 31, 2022 96.14 Mn
Dec 31, 2021 -19.20 Mn
Sep 30, 2021 -32.08 Mn
Jun 30, 2021 -31.95 Mn
Mar 31, 2021 -27.52 Mn